Is Spotify a Millionaire-Maker Stock?
Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…
Sell
40
TMO Quote, Financials, Valuation and Earnings
Last price:
$402.88
Seasonality move
:
2.35%
Day range:
$402.81 - $415.75
52-week range:
$402.81 - $627.88
Dividend yield:
0.39%
P/E ratio:
24.09x
P/S ratio:
3.66x
P/B ratio:
3.14x
Volume:
3M
Avg. volume:
2.9M
1-year change:
-28.39%
Market cap:
$155.1B
Revenue:
$42.9B
EPS (TTM):
$17.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$10.2B | $5.10 | 1.3% | 30.25% | $570.17 |
|
APDN
Applied DNA Sciences
|
$1.2M | -$3.00 | 27.47% | -98.87% | -- |
|
FONR
Fonar
|
-- | -- | -- | -- | -- |
|
PRPH
ProPhase Labs
|
$2.5M | -$0.18 | -32.58% | -48.57% | $13.80 |
|
VCYT
Veracyte
|
$111M | $0.20 | 6.64% | 338.71% | $40.50 |
|
XWEL
XWELL
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$410.78 | $570.17 | $155.1B | 24.09x | $0.43 | 0.39% | 3.66x |
|
APDN
Applied DNA Sciences
|
$0.85 | -- | $933.7K | -- | $0.00 | 0% | 0.05x |
|
FONR
Fonar
|
$12.55 | -- | $79.5M | 10.91x | $0.00 | 0% | 0.79x |
|
PRPH
ProPhase Labs
|
$0.30 | $13.80 | $12.7M | -- | $0.00 | 0% | 0.92x |
|
VCYT
Veracyte
|
$31.21 | $40.50 | $2.4B | 76.12x | $0.00 | 0% | 5.33x |
|
XWEL
XWELL
|
$0.86 | -- | $4.5M | -- | $0.00 | 0% | 0.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
40.91% | 1.040 | 18.19% | 1.20x |
|
APDN
Applied DNA Sciences
|
-- | 5.301 | -- | 4.28x |
|
FONR
Fonar
|
0.03% | 1.233 | 0.07% | 10.85x |
|
PRPH
ProPhase Labs
|
31.06% | -4.436 | 37.21% | 1.12x |
|
VCYT
Veracyte
|
-- | 3.551 | -- | 4.54x |
|
XWEL
XWELL
|
-- | -0.848 | -- | 1.72x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMO
Thermo Fisher Scientific
|
$4.2B | $1.8B | 7.88% | 13.49% | 18.56% | $361M |
|
APDN
Applied DNA Sciences
|
$684.1K | -$3M | -113.07% | -113.07% | -247.7% | -$3.4M |
|
FONR
Fonar
|
$9.7M | $2.4M | 4.95% | 4.95% | 11.92% | $1.5M |
|
PRPH
ProPhase Labs
|
-$165K | -$7.9M | -47.22% | -59.59% | -252.29% | -$4.2M |
|
VCYT
Veracyte
|
$79.5M | $1.2M | 2.85% | 2.85% | 1.02% | $3.5M |
|
XWEL
XWELL
|
$2.1M | -$4.6M | -71.82% | -71.82% | -54.82% | -$3.8M |
Thermo Fisher Scientific vs. Competitors
-
Which has Higher Returns TMO or APDN?
Applied DNA Sciences has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of -220.57%. Thermo Fisher Scientific's return on equity of 13.49% beat Applied DNA Sciences's return on equity of -113.07%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.86% $3.98 $83.7B APDNApplied DNA Sciences57.17% -$28.00 $12.5M -
What do Analysts Say About TMO or APDN?
Thermo Fisher Scientific has a consensus price target of $570.17, signalling upside risk potential of 38.8%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 177225.93%. Given that Applied DNA Sciences has higher upside potential than Thermo Fisher Scientific, analysts believe Applied DNA Sciences is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 APDNApplied DNA Sciences0 1 0 -
Is TMO or APDN More Risky?
Thermo Fisher Scientific has a beta of 0.822, which suggesting that the stock is 17.823% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.491%.
-
Which is a Better Dividend Stock TMO or APDN?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or APDN?
Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than Applied DNA Sciences quarterly revenues of $1.2M. Thermo Fisher Scientific's net income of $1.5B is higher than Applied DNA Sciences's net income of -$2.6M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.09x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.66x versus 0.05x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific3.66x 24.09x $10.4B $1.5B APDNApplied DNA Sciences0.05x -- $1.2M -$2.6M
-
Which has Higher Returns TMO or FONR?
Fonar has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of 7.87%. Thermo Fisher Scientific's return on equity of 13.49% beat Fonar's return on equity of 4.95%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.86% $3.98 $83.7B FONRFonar39.03% $0.29 $159M -
What do Analysts Say About TMO or FONR?
Thermo Fisher Scientific has a consensus price target of $570.17, signalling upside risk potential of 38.8%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that Thermo Fisher Scientific has higher upside potential than Fonar, analysts believe Thermo Fisher Scientific is more attractive than Fonar.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 FONRFonar0 0 0 -
Is TMO or FONR More Risky?
Thermo Fisher Scientific has a beta of 0.822, which suggesting that the stock is 17.823% less volatile than S&P 500. In comparison Fonar has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.30600000000001%.
-
Which is a Better Dividend Stock TMO or FONR?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or FONR?
Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than Fonar quarterly revenues of $25M. Thermo Fisher Scientific's net income of $1.5B is higher than Fonar's net income of $2M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.09x while Fonar's PE ratio is 10.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.66x versus 0.79x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific3.66x 24.09x $10.4B $1.5B FONRFonar0.79x 10.91x $25M $2M
-
Which has Higher Returns TMO or PRPH?
ProPhase Labs has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of -209.38%. Thermo Fisher Scientific's return on equity of 13.49% beat ProPhase Labs's return on equity of -59.59%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.86% $3.98 $83.7B PRPHProPhase Labs-5.25% -$0.35 $55.3M -
What do Analysts Say About TMO or PRPH?
Thermo Fisher Scientific has a consensus price target of $570.17, signalling upside risk potential of 38.8%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 4439.47%. Given that ProPhase Labs has higher upside potential than Thermo Fisher Scientific, analysts believe ProPhase Labs is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 PRPHProPhase Labs0 0 0 -
Is TMO or PRPH More Risky?
Thermo Fisher Scientific has a beta of 0.822, which suggesting that the stock is 17.823% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.
-
Which is a Better Dividend Stock TMO or PRPH?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or PRPH?
Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than ProPhase Labs quarterly revenues of $3.1M. Thermo Fisher Scientific's net income of $1.5B is higher than ProPhase Labs's net income of -$6.6M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.09x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.66x versus 0.92x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific3.66x 24.09x $10.4B $1.5B PRPHProPhase Labs0.92x -- $3.1M -$6.6M
-
Which has Higher Returns TMO or VCYT?
Veracyte has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of 6.16%. Thermo Fisher Scientific's return on equity of 13.49% beat Veracyte's return on equity of 2.85%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.86% $3.98 $83.7B VCYTVeracyte69.46% $0.09 $1.2B -
What do Analysts Say About TMO or VCYT?
Thermo Fisher Scientific has a consensus price target of $570.17, signalling upside risk potential of 38.8%. On the other hand Veracyte has an analysts' consensus of $40.50 which suggests that it could grow by 29.77%. Given that Thermo Fisher Scientific has higher upside potential than Veracyte, analysts believe Thermo Fisher Scientific is more attractive than Veracyte.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 VCYTVeracyte7 2 1 -
Is TMO or VCYT More Risky?
Thermo Fisher Scientific has a beta of 0.822, which suggesting that the stock is 17.823% less volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.
-
Which is a Better Dividend Stock TMO or VCYT?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or VCYT?
Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than Veracyte quarterly revenues of $114.5M. Thermo Fisher Scientific's net income of $1.5B is higher than Veracyte's net income of $7M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.09x while Veracyte's PE ratio is 76.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.66x versus 5.33x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific3.66x 24.09x $10.4B $1.5B VCYTVeracyte5.33x 76.12x $114.5M $7M
-
Which has Higher Returns TMO or XWEL?
XWELL has a net margin of 14.54% compared to Thermo Fisher Scientific's net margin of -56.4%. Thermo Fisher Scientific's return on equity of 13.49% beat XWELL's return on equity of -71.82%.
Company Gross Margin Earnings Per Share Invested Capital TMOThermo Fisher Scientific40.86% $3.98 $83.7B XWELXWELL24.38% -$0.99 $14.8M -
What do Analysts Say About TMO or XWEL?
Thermo Fisher Scientific has a consensus price target of $570.17, signalling upside risk potential of 38.8%. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 712.35%. Given that XWELL has higher upside potential than Thermo Fisher Scientific, analysts believe XWELL is more attractive than Thermo Fisher Scientific.
Company Buy Ratings Hold Ratings Sell Ratings TMOThermo Fisher Scientific18 6 0 XWELXWELL0 0 0 -
Is TMO or XWEL More Risky?
Thermo Fisher Scientific has a beta of 0.822, which suggesting that the stock is 17.823% less volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.
-
Which is a Better Dividend Stock TMO or XWEL?
Thermo Fisher Scientific has a quarterly dividend of $0.43 per share corresponding to a yield of 0.39%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Thermo Fisher Scientific pays 9.2% of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend. Thermo Fisher Scientific's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TMO or XWEL?
Thermo Fisher Scientific quarterly revenues are $10.4B, which are larger than XWELL quarterly revenues of $8.4M. Thermo Fisher Scientific's net income of $1.5B is higher than XWELL's net income of -$4.8M. Notably, Thermo Fisher Scientific's price-to-earnings ratio is 24.09x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Thermo Fisher Scientific is 3.66x versus 0.12x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMOThermo Fisher Scientific3.66x 24.09x $10.4B $1.5B XWELXWELL0.12x -- $8.4M -$4.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Is a Millionaire-Maker Stock?
From time to time, investors will run across the term…
5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
99
DAVE alert for May 9
Dave [DAVE] is up 9.31% over the past day.
Buy
52
QDEL alert for May 9
QuidelOrtho [QDEL] is down 0.22% over the past day.
Buy
61
TPC alert for May 9
Tutor Perini [TPC] is up 9.61% over the past day.
